A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with metastatic prostate cancer

Study identifier:D3618C00002

ClinicalTrials.gov identifier:NCT04087174

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Metastatic Castration Resistant Prostate Cancer

Medical condition

prostate cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

Capivasertib, Enzalutamide, Abiraterone

Sex

Male

Actual Enrollment

27

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 05 Aug 2019
Primary Completion Date: 22 Jun 2021
Study Completion Date: 22 Jun 2021

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria